© 1998 by Oxford University Press
Journal Of The National Cancer Institute, Vol 90, 766-771, Copyright © 1998 by Oxford University Press
MW Kattan, JA Eastham, AM Stapleton, TM Wheeler and PT Scardino
BACKGROUND: Few published studies have combined clinical prognostic factors
into risk profiles that can be used to predict the likelihood of recurrence
or metastatic progression in patients following treatment of prostate
cancer. We developed a nomogram that allows prediction of disease
recurrence through use of preoperative clinical factors for patients with
clinically localized prostate cancer who are candidates for treatment with
a radical prostatectomy. METHODS: By use of Cox proportional hazards
regression analysis, we modeled the clinical data and disease follow-up for
983 men with clinically localized prostate cancer whom we intended to treat
with a radical prostatectomy. Clinical data included pretreatment serum
prostate-specific antigen levels, biopsy Gleason scores, and clinical
stage. Treatment failure was recorded when there was clinical evidence of
disease recurrence, a rising serum prostate-specific antigen level (two
measurements of 0.4 ng/mL or greater and rising), or initiation of adjuvant
therapy. Validation was performed on a separate sample of 168 men, also
from our institution. RESULTS: Treatment failure (i.e., cancer recurrence)
was noted in 196 of the 983 men, and the patients without failure had a
median follow-up of 30 months (range, 1-146 months). The 5-year probability
of freedom from failure for the cohort was 73% (95% confidence interval =
69%-76%). The predictions from the nomogram appeared accurate and
discriminating, with a validation sample area under the receiver operating
characteristic curve (i.e., comparison of the predicted probability with
the actual outcome) of 0.79. CONCLUSIONS: A nomogram has been developed
that can be used to predict the 5-year probability of treatment failure
among men with clinically localized prostate cancer treated with radical
prostatectomy.
ARTICLES
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
Information Technology Program, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. A. Brown, F. Lindmark, P. Stattin, K. Balter, H.-O. Adami, S. L. Zheng, J. Xu, W. B. Isaacs, H. Gronberg, S. N. Breit, et al. Macrophage Inhibitory Cytokine 1: A New Prognostic Marker in Prostate Cancer Clin. Cancer Res., November 1, 2009; 15(21): 6658 - 6664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Stephenson, M. W. Kattan, J. A. Eastham, F. J. Bianco Jr, O. Yossepowitch, A. J. Vickers, E. A. Klein, D. P. Wood, and P. T. Scardino Prostate Cancer-Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era J. Clin. Oncol., September 10, 2009; 27(26): 4300 - 4305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Cooperberg, S. Hinotsu, M. Namiki, K. Ito, J. Broering, P. R. Carroll, and H. Akaza Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy J. Clin. Oncol., September 10, 2009; 27(26): 4306 - 4313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. BICKERS and C. AUKIM-HASTIE New Molecular Biomarkers for the Prognosis and Management of Prostate Cancer - The Post PSA Era Anticancer Res, August 1, 2009; 29(8): 3289 - 3298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Cooperberg, J. M. Broering, and P. R. Carroll Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis J Natl Cancer Inst, June 16, 2009; 101(12): 878 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shukla-Dave, H. Hricak, N. Ishill, C. S. Moskowitz, M. Drobnjak, V. E. Reuter, K. L. Zakian, P. T. Scardino, and C. Cordon-Cardo Prediction of Prostate Cancer Recurrence Using Magnetic Resonance Imaging and Molecular Profiles Clin. Cancer Res., June 1, 2009; 15(11): 3842 - 3849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Ma, H. Kantarjian, B. Bekele, A. C. Donahue, X. Zhang, Z. J. Zhang, S. O'Brien, E. Estey, Z. Estrov, J. Cortes, et al. Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome Clin. Cancer Res., June 1, 2009; 15(11): 3820 - 3826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Kim, S.-Y. Lee, T. R. Lee, W. H. Cho, W. S. Song, J.-S. Koh, J. A. Lee, J. Y. Yoo, and D.-G Jeon Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma Ann. Onc., May 1, 2009; 20(5): 955 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W.F. Catto, M. F. Abbod, D. A. Linkens, S. Larre, D. J. Rosario, and F. C. Hamdy Neurofuzzy Modeling to Determine Recurrence Risk Following Radical Cystectomy for Nonmetastatic Urothelial Carcinoma of the Bladder Clin. Cancer Res., May 1, 2009; 15(9): 3150 - 3155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Z. Qian, C.-Y. Huang, C. A. O'Brien, I. M. Coleman, M. Garzotto, L. D. True, C. S. Higano, R. Vessella, P. H. Lange, P. S. Nelson, et al. Prostate Cancer-Associated Gene Expression Alterations Determined from Needle Biopsies Clin. Cancer Res., May 1, 2009; 15(9): 3135 - 3142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Shariat, P. I. Karakiewicz, G. Godoy, and S. P. Lerner Review: Use of nomograms for predictions of outcome in patients with advanced bladder cancer Therapeutic Advances in Urology, April 1, 2009; 1(1): 13 - 26. [Abstract] [PDF]
|
|
|
|
|
|
W. G. Wierda, S. O'Brien, X. Wang, S. Faderl, A. Ferrajoli, K.-A. Do, G. Garcia-Manero, J. Cortes, D. Thomas, C. Koller, et al. Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment J. Clin. Oncol., April 1, 2009; 27(10): 1637 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-H. Wang, Y. Y. Shugart, S. R. Cole, and E. A. Platz A Simulation Study of Control Sampling Methods for Nested Case-Control Studies of Genetic and Molecular Biomarkers and Prostate Cancer Progression Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 706 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kollermann, S. Weikert, M. Schostak, C. Kempkensteffen, K. Kleinschmidt, T. Rau, and K. Pantel Prognostic Significance of Disseminated Tumor Cells in the Bone Marrow of Prostate Cancer Patients Treated With Neoadjuvant Hormone Treatment J. Clin. Oncol., October 20, 2008; 26(30): 4928 - 4933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M.G. Taylor, D. P. Ankerst, and R. R. Andridge Validation of Biomarker-Based Risk Prediction Models Clin. Cancer Res., October 1, 2008; 14(19): 5977 - 5983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Klein, A. J. Stephenson, D. Raghavan, and R. Dreicer Systems Pathology and Predicting Outcome After Radical Prostatectomy J. Clin. Oncol., August 20, 2008; 26(24): 3916 - 3917. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Donovan, S. Hamann, M. Clayton, F. M. Khan, M. Sapir, V. Bayer-Zubek, G. Fernandez, R. Mesa-Tejada, M. Teverovskiy, V. E. Reuter, et al. Systems Pathology Approach for the Prediction of Prostate Cancer Progression After Radical Prostatectomy J. Clin. Oncol., August 20, 2008; 26(24): 3923 - 3929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Grimes The Nomogram Epidemic: Resurgence of a Medical Relic Ann Intern Med, August 19, 2008; 149(4): 273 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Shariat, P. I. Karakiewicz, N. Suardi, and M. W. Kattan Comparison of Nomograms With Other Methods for Predicting Outcomes in Prostate Cancer: A Critical Analysis of the Literature Clin. Cancer Res., July 15, 2008; 14(14): 4400 - 4407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Mucci, Y. Pawitan, F. Demichelis, K. Fall, J. R. Stark, H.-O. Adami, S.-O. Andersson, O. Andren, A. Eisenstein, L. Holmberg, et al. Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1682 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Shariat, J. A. Karam, J. Walz, C. G. Roehrborn, F. Montorsi, V. Margulis, F. Saad, K. M. Slawin, and P. I. Karakiewicz Improved Prediction of Disease Relapse after Radical Prostatectomy through a Panel of Preoperative Blood-Based Biomarkers Clin. Cancer Res., June 15, 2008; 14(12): 3785 - 3791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Svatek, J. A. Karam, C. G. Roehrborn, P. I. Karakiewicz, K. M. Slawin, and S. F. Shariat Preoperative Plasma Endoglin Levels Predict Biochemical Progression After Radical Prostatectomy Clin. Cancer Res., June 1, 2008; 14(11): 3362 - 3366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Garcia, E. A. Klein, C. Magi-Galluzzi, P. Elson, P. Triozzi, and R. Dreicer Clinical and Biological Effects of Neoadjuvant Sargramostim and Thalidomide in Patients with Locally Advanced Prostate Carcinoma Clin. Cancer Res., May 15, 2008; 14(10): 3052 - 3059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Shariat, J. Walz, C. G. Roehrborn, A. R. Zlotta, P. Perrotte, N. Suardi, F. Saad, and P. I. Karakiewicz External Validation of a Biomarker-Based Preoperative Nomogram Predicts Biochemical Recurrence After Radical Prostatectomy J. Clin. Oncol., March 20, 2008; 26(9): 1526 - 1531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Laxman, D. S. Morris, J. Yu, J. Siddiqui, J. Cao, R. Mehra, R. J. Lonigro, A. Tsodikov, J. T. Wei, S. A. Tomlins, et al. A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer Cancer Res., February 1, 2008; 68(3): 645 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Weiser, R. G. Landmann, M. W. Kattan, M. Gonen, J. Shia, J. Chou, P. B. Paty, J. G. Guillem, L. K. Temple, D. Schrag, et al. Individualized Prediction of Colon Cancer Recurrence Using a Nomogram J. Clin. Oncol., January 20, 2008; 26(3): 380 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Veltri, M. C. Miller, S. Isharwal, C. Marlow, D. V. Makarov, and A. W. Partin Prediction of Prostate-Specific Antigen Recurrence in Men with Long-term Follow-up Postprostatectomy Using Quantitative Nuclear Morphometry Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 102 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Mucci, Y. Pawitan, F. Demichelis, K. Fall, J. R. Stark, H.-O. Adami, S.-O. Andersson, O. Andren, A. S. Eisenstein, L. Holmberg, et al. Nine-Gene Molecular Signature Is Not Associated with Prostate Cancer Death in a Watchful Waiting Cohort Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 249 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Armstrong, E. S. Garrett-Mayer, Y.-C. O. Yang, R. de Wit, I. F. Tannock, and M. Eisenberger A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis Clin. Cancer Res., November 1, 2007; 13(21): 6396 - 6403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Bjartell, H. Al-Ahmadie, A. M. Serio, J. A. Eastham, S. E. Eggener, S. W. Fine, L. Udby, W. L. Gerald, A. J. Vickers, H. Lilja, et al. Association of Cysteine-Rich Secretory Protein 3 and {beta}-Microseminoprotein with Outcome after Radical Prostatectomy Clin. Cancer Res., July 15, 2007; 13(14): 4130 - 4138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Wierda, S. O'Brien, X. Wang, S. Faderl, A. Ferrajoli, K.-A. Do, J. Cortes, D. Thomas, G. Garcia-Manero, C. Koller, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia Blood, June 1, 2007; 109(11): 4679 - 4685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Stephenson, P. T. Scardino, M. W. Kattan, T. M. Pisansky, K. M. Slawin, E. A. Klein, M. S. Anscher, J. M. Michalski, H. M. Sandler, D. W. Lin, et al. Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy J. Clin. Oncol., May 20, 2007; 25(15): 2035 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Banyard, L. Bao, M. D. Hofer, D. Zurakowski, K. A. Spivey, A. S. Feldman, L. M. Hutchinson, R. Kuefer, M. A. Rubin, and B. R. Zetter Collagen XXIII Expression Is Associated with Prostate Cancer Recurrence and Distant Metastases Clin. Cancer Res., May 1, 2007; 13(9): 2634 - 2642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C Perez-Martinez, V. Alonso, J. L Sarasa, S.-G. Nam-Cha, R. Vela-Navarrete, F. Manzarbeitia, F. J Calahorra, and P. Esbrit Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligand J. Clin. Pathol., March 1, 2007; 60(3): 290 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Steuber, A. J. Vickers, A. M. Serio, V. Vaisanen, A. Haese, K. Pettersson, J. A. Eastham, P. T. Scardino, H. Huland, and H. Lilja Comparison of Free and Total Forms of Serum Human Kallikrein 2 and Prostate-Specific Antigen for Prediction of Locally Advanced and Recurrent Prostate Cancer Clin. Chem., February 1, 2007; 53(2): 233 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Shariat, P. I. Karakiewicz, G. S. Palapattu, G. E. Amiel, Y. Lotan, C. G. Rogers, A. Vazina, P. J. Bastian, A. Gupta, A. I. Sagalowsky, et al. Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy. Clin. Cancer Res., November 15, 2006; 12(22): 6663 - 6676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Vickers and E. B. Elkin Decision Curve Analysis: A Novel Method for Evaluating Prediction Models Med Decis Making, November 1, 2006; 26(6): 565 - 574. [Abstract] [PDF]
|
|
|
|
|
|
L. Lessard, P. I. Karakiewicz, P. Bellon-Gagnon, M. Alam-Fahmy, H. A. Ismail, A.-M. Mes-Masson, and F. Saad Nuclear Localization of Nuclear Factor-{kappa}B p65 in Primary Prostate Tumors Is Highly Predictive of Pelvic Lymph Node Metastases. Clin. Cancer Res., October 1, 2006; 12(19): 5741 - 5745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Svatek, J. J. Lee, C. G. Roehrborn, S. M. Lippman, and Y. Lotan The cost of prostate cancer chemoprevention: a decision analysis model. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1485 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Ferrari, N. N. Stone, R. Kurek, E. Mulligan, R. McGregor, R. Stock, P. Unger, U. Tunn, A. Kaisary, M. Droller, et al. Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes Is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment J. Clin. Oncol., July 1, 2006; 24(19): 3081 - 3088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Stephenson, P. T. Scardino, J. A. Eastham, F. J. Bianco Jr., Z. A. Dotan, P. A. Fearn, and M. W. Kattan Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst, May 17, 2006; 98(10): 715 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gleave and W. K. Kelly High-Risk Localized Prostate Cancer: A Case for Early Chemotherapy J. Clin. Oncol., November 10, 2005; 23(32): 8186 - 8191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Ryan and E. J. Small Early Versus Delayed Androgen Deprivation for Prostate Cancer: New Fuel for an Old Debate J. Clin. Oncol., November 10, 2005; 23(32): 8225 - 8231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Ferrone, M. W. Kattan, J. S. Tomlinson, S. P. Thayer, M. F. Brennan, and A. L. Warshaw Validation of a Postresection Pancreatic Adenocarcinoma Nomogram for Disease-Specific Survival J. Clin. Oncol., October 20, 2005; 23(30): 7529 - 7535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Strom, X. Wang, C. A. Pettaway, C. J. Logothetis, Y. Yamamura, K.-A. Do, R. J. Babaian, and P. Troncoso Obesity, Weight Gain, and Risk of Biochemical Failure among Prostate Cancer Patients following Prostatectomy Clin. Cancer Res., October 1, 2005; 11(19): 6889 - 6894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. I. Scher, M. J. Morris, W. K. Kelly, L. H. Schwartz, and G. Heller Prostate Cancer Clinical Trial End Points: "RECIST"ing a Step Backwards Clin. Cancer Res., July 15, 2005; 11(14): 5223 - 5232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Rubin, T. A. Bismar, O. Andren, L. Mucci, R. Kim, R. Shen, D. Ghosh, J. T. Wei, A. M. Chinnaiyan, H.-O. Adami, et al. Decreased {alpha}-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1424 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Bastian, G. S. Palapattu, X. Lin, S. Yegnasubramanian, L. A. Mangold, B. Trock, M. A. Eisenberger, A. W. Partin, and W. G. Nelson Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy Clin. Cancer Res., June 1, 2005; 11(11): 4037 - 4043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Bastian, J. Ellinger, A. Wellmann, N. Wernert, L. C. Heukamp, S. C. Muller, and A. von Ruecker Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene Loci Clin. Cancer Res., June 1, 2005; 11(11): 4097 - 4106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Zakian, K. Sircar, H. Hricak, H.-N. Chen, A. Shukla-Dave, S. Eberhardt, M. Muruganandham, L. Ebora, M. W. Kattan, V. E. Reuter, et al. Correlation of Proton MR Spectroscopic Imaging with Gleason Score Based on Step-Section Pathologic Analysis after Radical Prostatectomy Radiology, March 1, 2005; 234(3): 804 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Claus, H. Hricak, and R. R. Hattery Pretreatment Evaluation of Prostate Cancer: Role of MR Imaging and 1H MR Spectroscopy RadioGraphics, October 1, 2004; 24(suppl_1): S167 - S180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. DeWeese Radiation Therapy and Androgen Suppression as Treatment for Clinically Localized Prostate Cancer: The New Standard? JAMA, August 18, 2004; 292(7): 864 - 866. [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Smith, S. B. Malkowicz, R. Whittington, K. VanArsdalen, Z. Tochner, and A. J. Wein Identification of Clinically Significant Prostate Cancer by Prostate-Specific Antigen Screening Arch Intern Med, June 14, 2004; 164(11): 1227 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Cooperberg, D. P. Lubeck, M. V. Meng, S. S. Mehta, and P. R. Carroll The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management J. Clin. Oncol., June 1, 2004; 22(11): 2141 - 2149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, D. S. Coffey, B. A. Chabner, A. P. Dicker, K. Z. Guyton, P. D. Nisen, H. R. Soule, and A. V. D'Amico Prostate-Specific Antigen Doubling Time as a Surrogate Marker for Evaluation of Oncologic Drugs to Treat Prostate Cancer Clin. Cancer Res., June 1, 2004; 10(11): 3927 - 3933. [Full Text] [PDF]
|
|
|
|
|
|
S. F. Shariat, M. W. Kattan, E. Traxel, B. Andrews, K. Zhu, T. M. Wheeler, and K. M. Slawin Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor {beta}1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression Clin. Cancer Res., March 15, 2004; 10(6): 1992 - 1999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-E. Taplin and P. W. Kantoff The Ingredients for Prostate Cancer Nomograms: The Addition of Biomarkers Sets the Table for Future Recipes J. Clin. Oncol., October 1, 2003; 21(19): 3552 - 3553. [Full Text] [PDF]
|
|
|
|
|
|
M. W. Kattan, S. F. Shariat, B. Andrews, K. Zhu, E. Canto, K. Matsumoto, M. Muramoto, P. T. Scardino, M. Ohori, T. M. Wheeler, et al. The Addition of Interleukin-6 Soluble Receptor and Transforming Growth Factor Beta1 Improves a Preoperative Nomogram for Predicting Biochemical Progression in Patients With Clinically Localized Prostate Cancer J. Clin. Oncol., October 1, 2003; 21(19): 3573 - 3579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. D'Amico, J. W. Moul, P. R. Carroll, L. Sun, D. Lubeck, and M.-H. Chen Surrogate End Point for Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation Therapy J Natl Cancer Inst, September 17, 2003; 95(18): 1376 - 1383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Shariat, M. P. Roudier, G. E. Wilcox, M. W. Kattan, P. T. Scardino, R. L. Vessella, S. Erdamar, C. Nguyen, T. M. Wheeler, and K. M. Slawin Comparison of Immunohistochemistry with Reverse Transcription-PCR for the Detection of Micrometastatic Prostate Cancer in Lymph Nodes Cancer Res., August 1, 2003; 63(15): 4662 - 4670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Augustin, M. Graefen, J. Palisaar, J. Blonski, A. Erbersdobler, F. Daghofer, H. Huland, and P. G. Hammerer Prognostic Significance of Visible Lesions on Transrectal Ultrasound in Impalpable Prostate Cancers: Implications for Staging J. Clin. Oncol., August 1, 2003; 21(15): 2860 - 2868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Scardino The Prevention of Prostate Cancer -- The Dilemma Continues N. Engl. J. Med., July 17, 2003; 349(3): 297 - 299. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Henshall, D. E. H. Afar, J. Hiller, L. G. Horvath, D. I. Quinn, K. K. Rasiah, K. Gish, D. Willhite, J. G. Kench, M. Gardiner-Garden, et al. Survival Analysis of Genome-Wide Gene Expression Profiles of Prostate Cancers Identifies New Prognostic Targets of Disease Relapse Cancer Res., July 15, 2003; 63(14): 4196 - 4203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. D'Amico, J. Moul, P. R. Carroll, L. Sun, D. Lubeck, and M.-H. Chen Cancer-Specific Mortality After Surgery or Radiation for Patients With Clinically Localized Prostate Cancer Managed During the Prostate-Specific Antigen Era J. Clin. Oncol., June 1, 2003; 21(11): 2163 - 2172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kuniyasu, R. Ukai, D. Johnston, P. Troncoso, I. J. Fidler, and C. A. Pettaway The Relative mRNA Expression Levels of Matrix Metalloproteinase to E-Cadherin in Prostate Biopsy Specimens Distinguishes Organ-confined from Advanced Prostate Cancer at Radical Prostatectomy Clin. Cancer Res., June 1, 2003; 9(6): 2185 - 2194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Spencer, M. Steinberg, J. Malin, J. Adams, and M. S. Litwin Quality-of-Care Indicators for Early-Stage Prostate Cancer J. Clin. Oncol., May 15, 2003; 21(10): 1928 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Rhodes, M. G. Sanda, A. P. Otte, A. M. Chinnaiyan, and M. A. Rubin Multiplex Biomarker Approach for Determining Risk of Prostate-Specific Antigen-Defined Recurrence of Prostate Cancer J Natl Cancer Inst, May 7, 2003; 95(9): 661 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Shariat, M. W. Kattan, S. Erdamar, C. Nguyen, P. T. Scardino, D. M. Spencer, T. M. Wheeler, and K. M. Slawin Detection of Clinically Significant, Occult Prostate Cancer Metastases in Lymph Nodes Using a Splice Variant-Specific RT-PCR Assay for Human Glandular Kallikrein J. Clin. Oncol., April 1, 2003; 21(7): 1223 - 1231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Morris and H. I. Scher Clinical Approaches to Osseous Metastases in Prostate Cancer Oncologist, April 1, 2003; 8(2): 161 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Matsui, S. Egawa, C. Tsukayama, A. Terai, S. Kuwao, S. Baba, and Y. Arai Artificial Neural Network Analysis for Predicting Pathological Stage of Clinically Localized Prostate Cancer in the Japanese Population Jpn. J. Clin. Oncol., December 1, 2002; 32(12): 530 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. D'Amico, K. Cote, M. Loffredo, A. A. Renshaw, and D. Schultz Determinants of Prostate Cancer-Specific Survival After Radiation Therapy for Patients With Clinically Localized Prostate Cancer J. Clin. Oncol., December 1, 2002; 20(23): 4567 - 4573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Shariat, E. Gottenger, C. Nguyen, W. Song, M. W. Kattan, J. Andenoro, T. M. Wheeler, D. M. Spencer, and K. M. Slawin Preoperative Blood Reverse Transcriptase-PCR Assays for Prostate-specific Antigen and Human Glandular Kallikrein for Prediction of Prostate Cancer Progression after Radical Prostatectomy Cancer Res., October 15, 2002; 62(20): 5974 - 5979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Smaletz, H. I. Scher, E. J. Small, D. A. Verbel, A. McMillan, K. Regan, W. K. Kelly, and M. W. Kattan Nomogram for Overall Survival of Patients With Progressive Metastatic Prostate Cancer After Castration J. Clin. Oncol., October 1, 2002; 20(19): 3972 - 3982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. D'Amico Predicting Prostate-Specific Antigen Recurrence Established: Now, Who Will Survive? J. Clin. Oncol., August 1, 2002; 20(15): 3188 - 3190. [Full Text] [PDF]
|
|
|
|
|
|
M. Graefen, P. I. Karakiewicz, I. Cagiannos, D. I. Quinn, S. M. Henshall, J. J. Grygiel, R. L. Sutherland, P. D. Stricker, E. Klein, P. Kupelian, et al. International Validation of a Preoperative Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy J. Clin. Oncol., August 1, 2002; 20(15): 3206 - 3212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Cross, D. Shultz, S. B. Malkowicz, W. C. Huang, R. Whittington, J. E. Tomaszewski, A. A. Renshaw, J. P. Richie, and A. V. D'Amico Impact of Race on Prostate-Specific Antigen Outcome After Radical Prostatectomy for Clinically Localized Adenocarcinoma of the Prostate J. Clin. Oncol., June 15, 2002; 20(12): 2863 - 2868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Cagiannos, M. Graefen, P. I. Karakiewicz, M. Ohori, J. A. Eastham, F. Rabbani, W. Fair, T. M. Wheeler, P. G. Hammerer, A. Haese, et al. Analysis of Clinical Stage T2 Prostate Cancer: Do Current Subclassifications Represent an Improvement? J. Clin. Oncol., April 15, 2002; 20(8): 2025 - 2030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nunez, H. A. Macapinlac, H. W.D. Yeung, T. Akhurst, S. Cai, I. Osman, M. Gonen, E. Riedel, H. I. Scher, and S. M. Larson Combined 18F-FDG and 11C-Methionine PET Scans in Patients with Newly Progressive Metastatic Prostate Cancer J. Nucl. Med., January 1, 2002; 43(1): 46 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. I. Quinn, S. M. Henshall, A.-M. Haynes, P. C. Brenner, R. Kooner, D. Golovsky, J. Mathews, G. F. O'Neill, J. J. Turner, W. Delprado, et al. Prognostic Significance of Pathologic Features in Localized Prostate Cancer Treated With Radical Prostatectomy: Implications for Staging Systems and Predictive Models J. Clin. Oncol., August 15, 2001; 19(16): 3692 - 3705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Shariat, M. Shalev, A. Menesses-Diaz, I. Y. Kim, M. W. Kattan, T. M. Wheeler, and K. M. Slawin Preoperative Plasma Levels of Transforming Growth Factor Beta1 (TGF-{beta}1) Strongly Predict Progression in Patients Undergoing Radical Prostatectomy J. Clin. Oncol., June 1, 2001; 19(11): 2856 - 2864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Crook, H. Lukka, L. Klotz, N. Bestic, and M. Johnston Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer Can. Med. Assoc. J., April 1, 2001; 164(7): 975 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Haut, J. F. Harryhill, J. Rosenstock, M. J. Warhol, and R. Vitti Progressing Prostate Carcinoma Oncologist, April 1, 2001; 6(2): 183 - 196. [Abstract] [Full Text]
|
|
|
|
|
|
S. M. Henshall, D. I. Quinn, C. S. Lee, D. R. Head, D. Golovsky, P. C. Brenner, W. Delprado, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland Overexpression of the Cell Cycle Inhibitor p16INK4A in High-grade Prostatic Intraepithelial Neoplasia Predicts Early Relapse in Prostate Cancer Patients Clin. Cancer Res., March 1, 2001; 7(3): 544 - 550. [Abstract] [Full Text]
|
|
|
|
|
|
S. Egawa, K. Suyama, Y. Arai, K. Matsumoto, C. Tsukayama, S. Kuwao, and S. Baba A Study of Pretreatment Nomograms to Predict Pathological Stage and Biochemical Recurrence After Radical Prostatectomy for Clinically Resectable Prostate Cancer in Japanese Men Jpn. J. Clin. Oncol., February 1, 2001; 31(2): 74 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Slawin, S. F. Shariat, C. Nguyen, A. K. Leventis, W. Song, M. W. Kattan, C. Y. F. Young, D. J. Tindall, and T. M. Wheeler Detection of Metastatic Prostate Cancer Using a Splice Variant-specific Reverse Transcriptase-Polymerase Chain Reaction Assay for Human Glandular Kallikrein Cancer Res., December 1, 2000; 60(24): 7142 - 7148. [Abstract] [Full Text]
|
|
|
|
|
|
M. W. Kattan, M. J. Zelefsky, P. A. Kupelian, P. T. Scardino, Z. Fuks, and S. A. Leibel Pretreatment Nomogram for Predicting the Outcome of Three-Dimensional Conformal Radiotherapy in Prostate Cancer J. Clin. Oncol., October 19, 2000; 18(19): 3352 - 3359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kuniyasu, P. Troncoso, D. Johnston, C. D. Bucana, E. Tahara, I. J. Fidler, and C. A. Pettaway Relative Expression of Type IV Collagenase, E-cadherin, and Vascular Endothelial Growth Factor/Vascular Permeability Factor in Prostatectomy Specimens Distinguishes Organ-confined from Pathologically Advanced Prostate Cancers Clin. Cancer Res., June 1, 2000; 6(6): 2295 - 2308. [Abstract] [Full Text]
|
|
|
|
|
|
A. V. D’Amico, R. Whittington, S. B. Malkowicz, D. Schultz, J. Fondurulia, M.-H. Chen, J. E. Tomaszewski, A. A. Renshaw, A. Wein, and J. P. Richie Clinical Utility of the Percentage of Positive Prostate Biopsies in Defining Biochemical Outcome After Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer J. Clin. Oncol., March 13, 2000; 18(6): 1164 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Yang, L. D. Truong, T. M. Wheeler, and T. C. Thompson Caveolin-1 Expression in Clinically Confined Human Prostate Cancer: A Novel Prognostic Marker Cancer Res., November 1, 1999; 59(22): 5719 - 5723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. U. Shipley, H. D. Thames, H. M. Sandler, G. E. Hanks, A. L. Zietman, C. A. Perez, D. A. Kuban, S. L. Hancock, and C. D. Smith Radiation Therapy for Clinically Localized Prostate Cancer: A Multi-institutional Pooled Analysis JAMA, May 5, 1999; 281(17): 1598 - 1604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. I. Scher Management of Prostate Cancer After Prostatectomy: Treating the Patient, Not the PSA JAMA, May 5, 1999; 281(17): 1642 - 1645. [Full Text] [PDF]
|
|
|
|
|
|
M. W. Kattan, T. M. Wheeler, and P. T. Scardino Postoperative Nomogram for Disease Recurrence After Radical Prostatectomy for Prostate Cancer J. Clin. Oncol., May 1, 1999; 17(5): 1499 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. D'Amico, R. Whittington, S. B. Malkowicz, J. Fondurulia, M.-H. Chen, I. Kaplan, C. J. Beard, J. E. Tomaszewski, A. A. Renshaw, A. Wein, et al. Pretreatment Nomogram for Prostate-Specific Antigen Recurrence After Radical Prostatectomy or External-Beam Radiation Therapy for Clinically Localized Prostate Cancer J. Clin. Oncol., January 1, 1999; 17(1): 168 - 168. [Abstract] [Full Text] [PDF]
|
|